Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis

Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0204121. doi: 10.1128/aac.02041-21. Epub 2022 Mar 9.

Abstract

We previously identified a series of triazolopyrimidines with antitubercular activity. We determined that Mycobacterium tuberculosis strains with mutations in QcrB, a subunit of the cytochrome bcc-aa3 supercomplex, were resistant. A cytochrome bd oxidase deletion strain was more sensitive to this series. We isolated resistant mutants with mutations in Rv1339. Compounds led to the depletion of intracellular ATP levels and were active against intracellular bacteria, but they did not inhibit human mitochondrial respiration. These data are consistent with triazolopyrimidines acting via inhibition of QcrB.

Keywords: aerobic respiration; antibiotic resistance; antibiotic tolerance; tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Cytochromes
  • Electron Transport Complex IV / genetics
  • Electron Transport Complex IV / metabolism
  • Humans
  • Mycobacterium tuberculosis* / genetics
  • Mycobacterium tuberculosis* / metabolism
  • Respiration

Substances

  • Antitubercular Agents
  • Cytochromes
  • Electron Transport Complex IV